
Robert-Jan M Van Geuns

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8590626/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
2	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
3	Coronary angiography with multi-slice computed tomography. Lancet, The, 2001, 357, 599-603.	13.7	665
4	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. New England Journal of Medicine, 2010, 363, 136-146.	27.0	608
5	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet, The, 2008, 372, 1163-1173.	13.7	607
6	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
7	Evaluation of the Accuracy of Gadolinium-Enhanced Cardiovascular Magnetic Resonance in the Diagnosis of Cardiac Sarcoidosis. Journal of the American College of Cardiology, 2005, 45, 1683-1690.	2.8	519
8	Catheter-Based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure. Journal of the American College of Cardiology, 2003, 42, 2063-2069.	2.8	516
9	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet, The, 2012, 380, 1482-1490.	13.7	412
10	Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis. Journal of the American College of Cardiology, 2011, 58, 1578-1588.	2.8	410
11	In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. European Heart Journal, 2014, 35, 639-647.	2.2	314
12	Prognostic Value of Microvascular Obstruction and Infarct Size, as MeasuredÂby CMR in STEMI Patients. JACC: Cardiovascular Imaging, 2014, 7, 930-939.	5.3	271
13	An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. European Heart Journal, 2010, 31, 165-176.	2.2	239
14	Fractional Flow Reserve Computed from Noninvasive CT Angiography Data: Diagnostic Performance of an On-Site Clinician-operated Computational Fluid Dynamics Algorithm. Radiology, 2015, 274, 674-683.	7.3	218
15	Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention, 2014, 9, 1271-1284.	3.2	212
16	Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement. Circulation, 2013, 127, 2194-2201.	1.6	204
17	Evaluation of Left Ventricular Function Three Years After Percutaneous Recanalization of Chronic Total Coronary Occlusions. American Journal of Cardiology, 2008, 101, 179-185.	1.6	202
18	Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. Journal of the American College of Cardiology, 2010, 56, 272-277.	2.8	198

#	Article	IF	CITATIONS
19	Prediction of Left Ventricular Function After Drug-Eluting Stent Implantation for Chronic Total Coronary Occlusions. Journal of the American College of Cardiology, 2006, 47, 721-725.	2.8	189
20	First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold. Circulation: Cardiovascular Interventions, 2012, 5, 620-632.	3.9	186
21	Usefulness of multislice computed tomography for detecting obstructive coronary artery disease. American Journal of Cardiology, 2002, 89, 913-918.	1.6	185
22	Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2022, 327, 1771.	7.4	185
23	Evaluation of Patients after Coronary Artery Bypass Surgery: CT Angiographic Assessment of Grafts and Coronary Arteries. Radiology, 2003, 229, 749-756.	7.3	180
24	Prospective Assessment of the DiagnosticÂAccuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance. JACC: Cardiovascular Interventions, 2015, 8, 824-833.	2.9	172
25	Effects of Primary Angioplasty for Acute Myocardial Infarction on Early and Late Infarct Size and Left Ventricular Wall Characteristics. Journal of the American College of Cardiology, 2006, 47, 40-44.	2.8	169
26	Near-Infrared Spectroscopy Predicts Cardiovascular Outcome in Patients WithÂCoronary Artery Disease. Journal of the American College of Cardiology, 2014, 64, 2510-2518.	2.8	162
27	Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. International Journal of Cardiology, 2015, 201, 684-691.	1.7	160
28	Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovascular Research, 2018, 114, 954-964.	3.8	148
29	A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis. Journal of the American College of Cardiology, 2016, 67, 766-776.	2.8	145
30	Cardiac Involvement in Patients With Pulmonary Sarcoidosis Assessed at Two University Medical Centers in the Netherlands. Chest, 2005, 128, 30-35.	0.8	143
31	Frequency and Causes of Stroke During or After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2012, 109, 1637-1643.	1.6	142
32	The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention, 2015, 10, 1396-1401.	3.2	139
33	Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?. European Heart Journal, 2012, 33, 1325-1333.	2.2	138
34	Multislice Computed Tomography and Magnetic Resonance Imaging for the Assessment of Reperfused Acute Myocardial Infarction. Journal of the American College of Cardiology, 2006, 48, 144-152.	2.8	137
35	PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis, 2016, 248, 117-122.	0.8	137
36	Fast virtual functional assessment of intermediate coronary lesions using routine angiographic data and blood flow simulation in humans: comparison with pressure wire – fractional flow reserve. EuroIntervention, 2014, 10, 574-583.	3.2	136

#	Article	IF	CITATIONS
37	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	3.2	131
38	Integrating CT Myocardial Perfusion andÂCT-FFR in the Work-Up ofÂCoronaryÂArteryÂDisease. JACC: Cardiovascular Imaging, 2017, 10, 760-770.	5.3	130
39	Intravenous Coronary Angiography by Electron Beam Computed Tomography. Circulation, 1998, 98, 2509-2512.	1.6	123
40	Diagnostic performance of stress myocardial perfusion imaging for coronary artery disease: a systematic review and meta-analysis. European Radiology, 2012, 22, 1881-1895.	4.5	123
41	Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. European Heart Journal, 2011, 32, 2454-2463.	2.2	121
42	Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. Atherosclerosis, 2015, 243, 560-566.	0.8	120
43	Diagnostic performance of hyperaemic myocardial blood flow index obtained by dynamic computed tomography: does it predict functionally significant coronary lesions?. European Heart Journal Cardiovascular Imaging, 2014, 15, 85-94.	1.2	119
44	Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovascular Research, 2020, 116, 787-805.	3.8	119
45	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?. Atherosclerosis, 2012, 221, 106-112.	0.8	115
46	Vascular Tissue Reaction to Acute Malapposition in Human Coronary Arteries. Circulation: Cardiovascular Interventions, 2012, 5, 20-29.	3.9	112
47	Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the â€~All-Comers' LEADERS Trial. Circulation: Cardiovascular Interventions, 2011, 4, 47-56.	3.9	109
48	The Additional Value of Gadolinium-Enhanced MRI to Standard Assessment for Cardiac Involvement in Patients With Pulmonary Sarcoidosis. Chest, 2005, 128, 1629-1637.	0.8	108
49	Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2014, 7, 1400-1411.	2.9	108
50	Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. European Heart Journal, 2014, 35, 777-786.	2.2	108
51	Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. American Heart Journal, 2011, 161, 771-781.	2.7	106
52	Complete Revascularization Is NotÂa Prerequisite for Success in Current Transcatheter Aortic Valve ImplantationÂPractice. JACC: Cardiovascular Interventions, 2013, 6, 867-875.	2.9	105
53	Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. Journal of Lipid Research, 2018, 59, 1729-1737.	4.2	105
54	Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study—TROFI trial. European Heart Journal, 2013, 34, 1050-1060.	2.2	103

#	Article	IF	CITATIONS
55	Accuracy and Reproducibility of Quantitation of Left Ventricular Function by Real-Time Three-Dimensional Echocardiography Versus Cardiac Magnetic Resonance. American Journal of Cardiology, 2008, 102, 778-783.	1.6	101
56	OCT Assessment of the Long-Term Vascular Healing Response 5 Years AfterÂEverolimus-Eluting BioresorbableÂVascular Scaffold. Journal of the American College of Cardiology, 2014, 64, 2343-2356.	2.8	101
57	First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography. EuroIntervention, 2011, 6, 1037-1045.	3.2	99
58	The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 432-441.	2.9	98
59	Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. European Heart Journal, 2018, 39, 295-302.	2.2	96
60	Angiographic and Optical Coherence Tomography Insights Into Bioresorbable Scaffold Thrombosis. Circulation: Cardiovascular Interventions, 2015, 8, .	3.9	90
61	Recovery of left ventricular function after primary angioplasty for acute myocardial infarction. European Heart Journal, 2005, 26, 1070-1077.	2.2	87
62	A Comparison between QLAB and TomTec Full Volume Reconstruction for Real Time Three-Dimensional Echocardiographic Quantification of Left Ventricular Volumes. Echocardiography, 2007, 24, 967-974.	0.9	87
63	Value of assessment of tricuspid annulus: real-time three-dimensional echocardiography and magnetic resonance imaging. International Journal of Cardiovascular Imaging, 2007, 23, 701-705.	1.5	82
64	Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and transâ€ŧhoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2011, 77, 868-875.	1.7	82
65	Self-Expanding Versus Balloon-Expandable Stents in Acute Myocardial Infarction: Results From the APPOSITION II Study. JACC: Cardiovascular Interventions, 2012, 5, 1209-1219.	2.9	82
66	Aortic annulus dimensions and leaflet calcification from contrast MSCT predict the need for balloon post-dilatation after TAVI with the Medtronic CoreValve prosthesis. EuroIntervention, 2011, 7, 564-572.	3.2	82
67	Quantitative cardiovascular magnetic resonance in pregnant women: cross-sectional analysis of physiological parameters throughout pregnancy and the impact of the supine position. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 31.	3.3	81
68	Changes in mitral regurgitation after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2010, 75, 43-49.	1.7	79
69	Usefulness of the SYNTAX Score to Predict "No Reflow―in Patients Treated With Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 109, 601-606.	1.6	78
70	NIRS and IVUS for Characterization of Atherosclerosis in Patients Undergoing Coronary Angiography. JACC: Cardiovascular Imaging, 2011, 4, 647-655.	5.3	76
71	Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. European Heart Journal, 2017, 38, 1969-1977.	2.2	76
72	Magnetic resonance imaging of haemorrhage within reperfused myocardial infarcts: possible interference with iron oxide-labelled cell tracking?. European Heart Journal, 2006, 27, 1620-1626.	2.2	73

#	Article	IF	CITATIONS
73	The influence of optimal medical treatment on the â€~obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study. BMJ Open, 2012, 2, e000535.	1.9	73
74	Tryton I, First-In-Man (FIM) study: six month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. EuroIntervention, 2008, 3, 546-552.	3.2	73
75	Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. Journal of Molecular and Cellular Cardiology, 2007, 42, 735-745.	1.9	72
76	Cardiac Involvement in Adults With m.3243A>G MELAS Gene Mutation. American Journal of Cardiology, 2007, 99, 264-269.	1.6	72
77	Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart, 2013, 99, 98-105.	2.9	72
78	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. JACC: Cardiovascular Interventions, 2019, 12, 2064-2075.	2.9	71
79	Automatic Quantitative Left Ventricular Analysis of Cine MR Images by Using Three-dimensional Information for Contour Detection. Radiology, 2006, 240, 215-221.	7.3	67
80	Detection and quantification of coronary atherosclerotic plaque by 64-slice multidetector CT: A systematic head-to-head comparison with intravascular ultrasound. Atherosclerosis, 2011, 219, 163-170.	0.8	67
81	Effect of Face-to-Face vs Virtual Reality Training on Cardiopulmonary Resuscitation Quality. JAMA Cardiology, 2020, 5, 328.	6.1	66
82	Diagnostic Accuracy and Clinical Utility of Noninvasive Testing for Coronary Artery Disease. Annals of Internal Medicine, 2010, 152, 630.	3.9	64
83	Quantification of myocardial blood flow by adenosine-stress CT perfusion imaging in pigs during various degrees of stenosis correlates well with coronary artery blood flow and fractional flow reserve. European Heart Journal Cardiovascular Imaging, 2013, 14, 331-338.	1.2	63
84	Quantification of Left Ventricular Volumes and Function in Patients with Cardiomyopathies by Real-time Three-dimensional Echocardiography: A Head-to-Head Comparison Between Two Different Semiautomated Endocardial Border Detection Algorithms. Journal of the American Society of Echocardiography, 2007, 20, 1042-1049.	2.8	61
85	Prosthesis–Patient Mismatch After Transcatheter Aortic Valve Implantation With the Medtronic CoreValve System in Patients With Aortic Stenosis. American Journal of Cardiology, 2010, 106, 255-260.	1.6	61
86	Relative Myocardial Blood Flow by Dynamic Computed Tomographic Perfusion Imaging Predicts Hemodynamic Significance of Coronary Stenosis Better Than Absolute Blood Flow. Investigative Radiology, 2014, 49, 801-807.	6.2	59
87	The Rotterdam Radial Access Research. Circulation: Cardiovascular Interventions, 2016, 9, e003129.	3.9	59
88	A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. European Heart Journal, 2011, 32, 294-304.	2.2	58
89	Effect of Experience on Results of Transcatheter Aortic Valve Implantation Using a Medtronic CoreValve System. American Journal of Cardiology, 2011, 107, 1824-1829.	1.6	57
90	Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments. Circulation Journal, 2012, 76, 1616-1623.	1.6	57

#	Article	IF	CITATIONS
91	Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. European Journal of Preventive Cardiology, 2016, 23, 552-558.	1.8	57
92	Reproducibility of coronary Fourier domain optical coherence tomography: quantitative analysis of in vivo stented coronary arteries using three different software packages. EuroIntervention, 2010, 6, 371-379.	3.2	57
93	Inâ€hospital complications after transcatheter aortic valve implantation revisited according to the valve academic research consortium definitions. Catheterization and Cardiovascular Interventions, 2011, 78, 457-467.	1.7	55
94	Three-dimensional optical frequency domain imaging in conventional percutaneous coronary intervention: the potential for clinical application. European Heart Journal, 2013, 34, 875-885.	2.2	54
95	Coronary Plaque Microstructure and Composition Modify Optical Polarization. JACC: Cardiovascular Imaging, 2018, 11, 1666-1676.	5.3	54
96	Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with <i>de novo</i> three-vessel disease: final results of the SYNTAX II study. European Heart Journal, 2022, 43, 1307-1316.	2.2	54
97	New Insights Into the Coronary Artery Bifurcation. JACC: Cardiovascular Interventions, 2011, 4, 921-931.	2.9	53
98	Circulating Osteoglycin and NGAL/MMP9 Complex Concentrations Predict 1-Year Major Adverse Cardiovascular Events After Coronary Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1078-1084.	2.4	53
99	Quantitative Computed Tomographic Coronary Angiography. Circulation: Cardiovascular Imaging, 2014, 7, 43-51.	2.6	53
100	TomografÃa de coherencia óptica de segunda generación en la práctica clÃnica. La adquisición de datos de alta velocidad muestra una reproducibilidad excelente en pacientes tratados con intervenciones coronarias percutáneas. Revista Espanola De Cardiologia, 2010, 63, 893-903.	1.2	52
101	Depression is independently associated with 7-year mortality in patients treated with percutaneous coronary intervention: Results from the RESEARCH registry. International Journal of Cardiology, 2013, 167, 2496-2501.	1.7	52
102	Technology Insight: magnetic navigation in coronary interventions. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 148-156.	3.3	51
103	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. Journal of the American College of Cardiology, 2017, 70, 60-74.	2.8	51
104	Coronary CT angiography derived fractional flow reserve: Methodology and evaluation of a point of care algorithm. Journal of Cardiovascular Computed Tomography, 2016, 10, 105-113.	1.3	50
105	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). American Journal of Cardiology, 2010, 105, 475-479.	1.6	49
106	Assessment of the safety and performance of the STENTYS self-expanding coronary stent in acute myocardial infarction: results from the APPOSITION I study. EuroIntervention, 2011, 7, 428-436.	3.2	49
107	Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. JACC: Cardiovascular Interventions, 2009, 2, 861-870.	2.9	48
108	Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up. JACC: Cardiovascular Interventions, 2011, 4, 789-799.	2.9	48

#	Article	IF	CITATIONS
109	Excess mortality in women compared to men after PCI in STEMI: An analysis of 11,931 patients during 2000–2009. International Journal of Cardiology, 2014, 176, 456-463.	1.7	48
110	1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds. JACC: Cardiovascular Interventions, 2014, 7, 482-493.	2.9	47
111	Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound. European Heart Journal Cardiovascular Imaging, 2017, 18, jew037.	1.2	47
112	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2012, 79, 219-228.	1.7	46
113	Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden. Atherosclerosis, 2014, 237, 84-91.	0.8	46
114	Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Failure, 2018, 5, 157-171.	3.1	46
115	Comparison of Contrast Agent–Enhanced Versus Non-Contrast Agent–Enhanced Real-Time Three-Dimensional Echocardiography for Analysis of Left Ventricular Systolic Function. American Journal of Cardiology, 2007, 100, 1485-1489.	1.6	45
116	Long-term tissue coverage of a biodegradable polylactide polymer–coated biolimus-eluting stent: Comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. American Heart Journal, 2011, 162, 922-931.	2.7	45
117	6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm. Journal of the American College of Cardiology, 2011, 58, 258-264.	2.8	44
118	Combining magnetic resonance viability variables better predicts improvement of myocardial function prior to percutaneous coronary intervention. International Journal of Cardiology, 2012, 159, 192-197.	1.7	44
119	Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). American Journal of Cardiology, 2014, 114, 1497-1503.	1.6	44
120	A novel method to assess coronary artery bifurcations by OCT: cut-plane analysis for side-branch ostial assessment from a main-vessel pullback. European Heart Journal Cardiovascular Imaging, 2015, 16, 177-189.	1.2	44
121	Addition of the Long-Axis Information to Short-Axis Contours Reduces Interstudy Variability of Left-Ventricular Analysis in Cardiac Magnetic Resonance Studies. Investigative Radiology, 2008, 43, 1-6.	6.2	42
122	Clinical outcome following transcatheter aortic valve implantation in patients with impaired left ventricular systolic function. Catheterization and Cardiovascular Interventions, 2012, 79, 702-710.	1.7	42
123	Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated at Cardiac hospital in Rotterdam for Investigation and Treatment of TCFA (SECRITT). EuroIntervention, 2012, 8, 945-954.	3.2	42
124	Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention, 2015, 11, 746-756.	3.2	42
125	Basic principles of magnetic resonance imagingâ~†. Progress in Cardiovascular Diseases, 1999, 42, 149-156.	3.1	41
126	Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. EuroIntervention, 2011, 7, 711-722.	3.2	41

Robert-Jan M Van Geuns

#	Article	IF	CITATIONS
127	Assessment of Coronary Atherosclerosis Progression and Regression at Bifurcations Using Combined IVUS and OCT. JACC: Cardiovascular Imaging, 2011, 4, 774-780.	5.3	40
128	First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era?. Nature Reviews Cardiology, 2009, 6, 374-378.	13.7	39
129	Cause of death after transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2014, 83, E277-82.	1.7	39
130	A Simplified Continuity Equation Approach to the Quantification of Stenotic Bicuspid Aortic Valves using Velocity-Encoded Cardiovascular Magnetic Resonance. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 899-906.	3.3	38
131	Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimusâ€eluting bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 880-888.	1.7	38
132	Late Cardiac Remodeling After Primary Percutaneous Coronary Intervention. Circulation Journal, 2013, 77, 81-88.	1.6	38
133	Prognostic Value of IntravascularÂUltrasound in PatientsÂWithÂCoronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 2003-2011.	2.8	38
134	True mitral annulus diameter is underestimated by two-dimensional echocardiography as evidenced by real-time three-dimensional echocardiography and magnetic resonance imaging. International Journal of Cardiovascular Imaging, 2007, 23, 541-547.	1.5	37
135	Limitation of Infarct Size and No-Reflow byÂIntracoronary Adenosine Depends Critically on Dose and Duration. JACC: Cardiovascular Interventions, 2015, 8, 1990-1999.	2.9	37
136	Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention, 2011, 7, 386-399.	3.2	37
137	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Heart, 2013, 99, 1267-1274.	2.9	36
138	High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study. Atherosclerosis, 2016, 247, 135-141.	0.8	36
139	The three year follow-up of the randomised "all-comers―trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). EuroIntervention, 2011, 7, 789-795.	3.2	36
140	Advanced three-dimensional quantitative coronary angiographic assessment of bifurcation lesions: methodology and phantom validation. EuroIntervention, 2013, 8, 1451-1460.	3.2	36
141	Remote Ischemic Conditioning in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Circulation Journal, 2012, 76, 2392-2404.	1.6	35
142	Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment. JACC: Cardiovascular Interventions, 2012, 5, 656-665.	2.9	35
143	Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: Results from the ATHEROREMO-IVUS study. Atherosclerosis, 2014, 236, 18-24.	0.8	35
144	Von Willebrand factor in relation to coronary plaque characteristics and cardiovascular outcome. Thrombosis and Haemostasis, 2015, 113, 577-584.	3.4	35

#	Article	IF	CITATIONS
145	Intravascular Polarimetry in Patients With Coronary Artery Disease. JACC: Cardiovascular Imaging, 2020, 13, 790-801.	5.3	35
146	Risks and benefits of percutaneous coronary intervention in spontaneous coronary artery dissection. Heart, 2021, 107, 1398-1406.	2.9	35
147	Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention, 2015, 10, 1288-1298.	3.2	34
148	Lipoprotein(a), Interleukinâ€10, Câ€Reactive Protein, and 8â€Year Outcome After Percutaneous Coronary Intervention. Clinical Cardiology, 2012, 35, 482-489.	1.8	33
149	Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. European Heart Journal Cardiovascular Imaging, 2014, 15, 987-995.	1.2	33
150	Diagnostic value of transmural perfusion ratio derived from dynamic CT-based myocardial perfusion imaging for the detection of haemodynamically relevant coronary artery stenosis. European Radiology, 2017, 27, 2309-2316.	4.5	33
151	The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3). EuroIntervention, 2012, 8, 235-241.	3.2	33
152	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice. JACC: Cardiovascular Interventions, 2011, 4, 887-895.	2.9	32
153	Validity and variability in visual assessment of stenosis severity in phantom bifurcation lesions: A survey in experts during the fifth meeting of the european bifurcation club. Catheterization and Cardiovascular Interventions, 2012, 79, 361-368.	1.7	32
154	Right ventricular involvement in cardiac sarcoidosis demonstrated with cardiac magnetic resonance. ESC Heart Failure, 2017, 4, 535-544.	3.1	32
155	Complete Percutaneous Revascularization for Multivessel Disease in Patients With Impaired Left Ventricular Function. JACC: Cardiovascular Interventions, 2010, 3, 392-400.	2.9	31
156	Impact of intra-aortic balloon pump support initiated before versus after primary percutaneous coronary intervention in patients with cardiogenic shock from acute myocardial infarction. International Journal of Cardiology, 2013, 168, 3758-3763.	1.7	31
157	Serial Assessment of Tissue Precursors andÂProgression of Coronary Calcification Analyzed by Fusion of IVUS and OCT. JACC: Cardiovascular Imaging, 2017, 10, 1151-1161.	5.3	31
158	Sixâ€month clinical followâ€up of the tryton side branch stent for the treatment of bifurcation lesions. Catheterization and Cardiovascular Interventions, 2011, 77, 798-806.	1.7	30
159	Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users. Netherlands Heart Journal, 2015, 23, 161-165.	0.8	30
160	Mid- to Long-Term Clinical Outcomes ofÂPatients Treated With the Everolimus-Eluting Bioresorbable VascularÂScaffold. JACC: Cardiovascular Interventions, 2016, 9, 1652-1663.	2.9	30
161	Residual atherothrombotic material after stenting in acute myocardial infarction — An optical coherence tomographic evaluation. International Journal of Cardiology, 2013, 167, 656-663.	1.7	29
162	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). EuroIntervention, 2016, 12, 1223-1230.	3.2	29

#	Article	IF	CITATIONS
163	Sex differences in plaque characteristics by intravascular imaging in patients with coronary artery disease. EuroIntervention, 2017, 13, 320-328.	3.2	28
164	Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. EuroIntervention, 2009, 5, F109-F111.	3.2	27
165	Rapid exchange ultra-thin microcatheter using fibre-optic sensing technology for measurement of intracoronary fractional flow reserve. EuroIntervention, 2015, 11, 428-432.	3.2	27
166	Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning. Basic Research in Cardiology, 2014, 109, 403.	5.9	26
167	Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention. EuroIntervention, 2017, 12, 1689-1696.	3.2	26
168	Short- and long-term outcomes in octogenarians undergoing percutaneous coronary intervention with stenting. EuroIntervention, 2012, 8, 920-928.	3.2	26
169	One-year clinical outcomes of the STENTYS Self-ApposingÂ [°] coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. EuroIntervention, 2015, 11, 264-271.	3.2	26
170	Rapid and accurate measurement of LV mass by biplane real-time 3D echocardiography in patients with concentric LV hypertrophy: Comparison to CMRâ~†. European Journal of Echocardiography, 2007, 9, 255-60.	2.3	25
171	Ascending Aortic Diameters in Congenital Aortic Stenosis: Cardiac Magnetic Resonance versus Transthoracic Echocardiography. Echocardiography, 2013, 30, 497-504.	0.9	25
172	Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy. European Heart Journal, 2014, 35, 1781-1781.	2.2	25
173	A simple risk chart for initial risk assessment of 30-day mortality in patients with cardiogenic shock from ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 101-107.	1.0	25
174	Comparison of coronary imaging between magnetic resonance imaging and electron beam computed tomography. American Journal of Cardiology, 2002, 90, 58-63.	1.6	24
175	Left Ventricular Volume Estimation in Cardiac Three-dimensional Ultrasound. Academic Radiology, 2005, 12, 1241-1249.	2.5	24
176	High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention, 2016, 12, 345-351.	3.2	24
177	Perforation of the Membranous Interventricular Septum After Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions, 2009, 2, 582-583.	3.9	23
178	Scaffold and Edge Vascular Response Following Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2014, 7, 1361-1369.	2.9	23
179	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	2.2	23
180	STENTYS Self-Apposing® sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. EuroIntervention, 2016, 11, e1267-e1274.	3.2	23

#	Article	IF	CITATIONS
181	Multislice Computed Tomography Angiography forÂNoninvasive Assessment of the 18-Month Performance of a Novel Radiolucent Bioresorbable Vascular Scaffolding Device. Journal of the American College of Cardiology, 2013, 62, 1813-1814.	2.8	22
182	Frequency, Determinants and Prognostic Implications of Infectious Complications After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2013, 112, 104-110.	1.6	22
183	IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). EBioMedicine, 2018, 36, 63-72.	6.1	22
184	The PulseCath iVAC 2L left ventricular assist device: conversion to a percutaneous transfemoral approach. EuroIntervention, 2015, 11, 835-839.	3.2	22
185	Acute procedural and six-month clinical outcome in patients treated with a dedicated bifurcation stent for left main stem disease: the TRYTON LM multicentre registry. EuroIntervention, 2013, 8, 1259-1269.	3.2	22
186	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. International Journal of Cardiovascular Imaging, 2011, 27, 859-866.	1.5	21
187	Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. EuroIntervention, 2016, 12, 30-37.	3.2	21
188	Relation of genetic profile and novel circulating biomarkers with coronary plaque phenotype as determined by intravascular ultrasound: rationale and design of the ATHEROREMO-IVUS study. EuroIntervention, 2014, 10, 953-960.	3.2	21
189	Patient Specific 4D Coronary Models from ECG-gated CTA Data for Intra-operative Dynamic Alignment of CTA with X-ray Images. Lecture Notes in Computer Science, 2009, 12, 369-376.	1.3	20
190	Impact of Coronary Remodeling on Fractional Flow Reserve. Circulation, 2018, 137, 747-749.	1.6	20
191	Design and principle of operation of the HeartMate PHP (percutaneous heart pump). EuroIntervention, 2018, 13, 1662-1666.	3.2	20
192	Serial In Vivo Intravascular Ultrasound-Based Echogenicity Changes of Everolimus-Eluting Bioresorbable Vascular Scaffold During the First 12 Months After Implantation. JACC: Cardiovascular Interventions, 2011, 4, 1281-1289.	2.9	19
193	Five-Year Optical Coherence Tomography Follow-Up of an Everolimus-Eluting Bioresorbable Vascular Scaffold. Circulation, 2012, 126, e89-91.	1.6	19
194	Rationale and design of the ARCUS: Effects of trAnsRadial perCUtaneouS coronary intervention on upper extremity function. Catheterization and Cardiovascular Interventions, 2016, 88, 1036-1043.	1.7	19
195	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention, 2011, 6, 928-935.	3.2	19
196	Intravenous coronary angiography using electron beam computed tomographyâ~†. Progress in Cardiovascular Diseases, 1999, 42, 139-148.	3.1	18
197	Accurate Automatic Papillary Muscle Identification for Quantitative Left Ventricle Mass Measurements in Cardiac Magnetic Resonance Imaging. Academic Radiology, 2008, 15, 1227-1233.	2.5	18
198	Additional Diagnostic Value of Integrated Analysis of Cardiac CTA and SPECT MPI Using the SMARTVis System in Patients with Suspected Coronary Artery Disease. Journal of Nuclear Medicine, 2014, 55, 50-57.	5.0	18

#	Article	IF	CITATIONS
199	Acute Gain in Minimal Lumen AreaÂFollowing Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds orÂXience Metallic Stents. JACC: Cardiovascular Interventions, 2016, 9, 1216-1227.	2.9	18
200	Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography. Coronary Artery Disease, 2017, 28, 23-32.	0.7	18
201	Repeatability Assessment of Intravascular Polarimetry in Patients. IEEE Transactions on Medical Imaging, 2018, 37, 1618-1625.	8.9	18
202	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open, 2019, 9, e026053.	1.9	18
203	Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH). EuroIntervention, 2014, 10, 236-240.	3.2	18
204	The Tryton Side Branch Stent. EuroIntervention, 2010, 6, J147-J150.	3.2	18
205	Magnetic navigation system used successfully to cross a crushed stent in a bifurcation that failed with conventional wires. Catheterization and Cardiovascular Interventions, 2007, 69, 852-855.	1.7	17
206	Integration of Multislice Computed Tomography With Magnetic Navigation Facilitates Percutaneous Coronary Interventions Without Additional Contrast Agents. Journal of the American College of Cardiology, 2009, 53, 741-746.	2.8	17
207	Intra-individual changes in anxiety and depression during 12-month follow-up in percutaneous coronary intervention patients. Journal of Affective Disorders, 2011, 134, 464-467.	4.1	17
208	Short- and Long-Term Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention with Stenting for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Cardiology, 2012, 121, 47-55.	1.4	17
209	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. European Heart Journal, 2022, 43, 1334-1344.	2.2	17
210	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study–Rationale and design of the PACMAN-AMI trial. American Heart Journal, 2021, 238, 33-44.	2.7	17
211	The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials. EuroIntervention, 2013, 9, 709-720.	3.2	17
212	Rotational angiography with motion compensation: first-in-man use for the 3D evaluation of transcatheter valve prostheses. EuroIntervention, 2015, 11, 442-449.	3.2	17
213	Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold. EuroIntervention, 2015, 11, 141-148.	3.2	17
214	Contractile Reserve in Segments With Nontransmural Infarction in Chronic Dysfunctional Myocardium Using Low-Dose Dobutamine CMR. JACC: Cardiovascular Imaging, 2010, 3, 614-622.	5.3	16
215	Three-Dimensional Reconstruction of the Post-Dilated ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold in a True Bifurcation Lesion for Flow Restoration. JACC: Cardiovascular Interventions, 2011, 4, 1149-1150.	2.9	16
216	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. American Heart Journal, 2011, 162, 1069-1079.e2.	2.7	16

#	Article	IF	CITATIONS
217	Impact of renal insufficiency on safety and efficacy of drugâ€eluting stents compared to bareâ€metal stents at 6 years. Catheterization and Cardiovascular Interventions, 2012, 80, 18-26.	1.7	16
218	Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: Results from the ATHEROREMO-IVUS study. International Journal of Cardiology, 2014, 177, 847-853.	1.7	16
219	Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Netherlands Heart Journal, 2015, 23, 153-160.	0.8	16
220	Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. EuroIntervention, 2011, 6, 1110-1116.	3.2	16
221	Magnetic resonance imaging of the coronary arteries: Techniques and resultsâ~†. Progress in Cardiovascular Diseases, 1999, 42, 157-166.	3.1	15
222	Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions. EuroIntervention, 2017, 13, 355-363.	3.2	15
223	The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound (ATHEROREMO-IVUS) study. EuroIntervention, 2018, 14, 194-203.	3.2	15
224	Culotte stenting with bioabsorbable everolimus-eluting stents. International Journal of Cardiology, 2013, 168, e35-e37.	1.7	14
225	Traumatic Coronary Artery Dissection. Circulation, 2013, 127, e280-2.	1.6	14
226	Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound. PLoS ONE, 2015, 10, e0141093.	2.5	14
227	Are BVS suitable for ACS patients? Support from a large single center real live registry. International Journal of Cardiology, 2016, 218, 89-97.	1.7	14
228	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology, 2020, 19, 179.	6.8	14
229	Incidence and potential mechanism of resolved, persistent and newly acquired malapposition three days after implantation of self-expanding or balloon-expandable stents in a STEMI population: insights from optical coherence tomography in the APPOSITION II study. EuroIntervention, 2015, 11, 885-894.	3.2	14
230	Rapid and Accurate Measurement of Left Ventricular Function with a New Second-Harmonic Fast-Rotating Transducer and Semi-Automated Border Detection. Echocardiography, 2006, 23, 447-454.	0.9	13
231	A randomized comparison of the magnetic navigation system versus conventional percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2008, 72, 761-770.	1.7	13
232	Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. European Heart Journal Cardiovascular Imaging, 2017, 18, 870-879.	1.2	13
233	Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0197119.	2.5	13
234	Final results of a self-apposing paclitaxel-eluting stent fOr the PErcutaNeous treatment of de novo lesions in native bifurcated coronary arteries study. EuroIntervention, 2016, 12, 356-358.	3.2	13

#	Article	IF	CITATIONS
235	Comparison of adenosine magnetic resonance perfusion imaging with invasive coronary flow reserve and fractional flow reserve in patients with suspected coronary artery disease. International Journal of Cardiology, 2011, 147, 184-186.	1.7	12
236	The Role of Self-expanding Stents in Patients with Atypical Coronary Anatomy. Interventional Cardiology Review, 2011, 9, 11.	1.6	12
237	Sevenâ€year safety and efficacy of the unrestricted use of drugâ€eluting stents in saphenous vein bypass grafts. Catheterization and Cardiovascular Interventions, 2012, 79, 912-918.	1.7	12
238	Ascending aorta dilatation in patients with bicuspid aortic valve stenosis: a prospective CMR study. European Radiology, 2013, 23, 642-649.	4.5	12
239	Temporal Evolution of Strut Light Intensity After Implantation of Bioresorbable Polymeric Intracoronary Scaffolds in the ABSORB Cohort B Trial. Circulation Journal, 2014, 78, 1873-1881.	1.6	12
240	Cardiac patients who completed a longitudinal psychosocial study had a different clinical and psychosocial baseline profile than patients who dropped out prematurely. European Journal of Preventive Cardiology, 2015, 22, 196-199.	1.8	12
241	Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial. EuroIntervention, 2020, 16, 645-653.	3.2	12
242	Optical coherence tomography for the assessment of pericardium covered stents for the treatment of degenerated saphenous vein grafts. EuroIntervention, 2010, 6, 78-85.	3.2	12
243	3-Dimensional optical frequency domain imaging for the evaluation of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. International Journal of Cardiology, 2011, 151, 103-105.	1.7	11
244	APPOSITION V: STENTYS coronary stent system clinical trial in subjects with ST-segment elevation myocardial infarction—Rationale and design. American Heart Journal, 2014, 168, 652-660.e2.	2.7	11
245	Is it safe to implant bioresorbable scaffolds in ostial side-branch lesions? Impact of â€~neo-carina' formation on main-branch flow pattern. Longitudinal clinical observations. Atherosclerosis, 2015, 238, 22-25.	0.8	11
246	Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial. American Heart Journal, 2017, 187, 104-111.	2.7	11
247	Automated characterisation of lipid core plaques in vivo by quantitative optical coherence tomography tissue type imaging. EuroIntervention, 2016, 12, 1490-1497.	3.2	11
248	Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study. EuroIntervention, 2017, 13, e540-e548.	3.2	11
249	Intravascular ultrasound radiofrequency analysis after optimal coronary stenting with initial quantitative coronary angiography guidance: an ATHEROREMO sub-study. EuroIntervention, 2011, 6, 977-984.	3.2	11
250	Health-related quality of life in the elderly three years after percutaneous coronary intervention. EuroIntervention, 2013, 9, 373-381.	3.2	11
251	Evaluation of pericardial hydatid cysts by different echocardiographic imaging modalities. International Journal of Cardiovascular Imaging, 2006, 22, 647-651.	1.5	10
252	Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study). Atherosclerosis, 2016, 254, 20-27.	0.8	10

#	Article	IF	CITATIONS
253	Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions. Netherlands Heart Journal, 2017, 25, 419-428.	0.8	10
254	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1083-1095.	3.3	10
255	The feasibility and safety of applying the Magnetic Navigation System to manage chronically occluded vessels: a single centre experience. EuroIntervention, 2011, 6, 711-716.	3.2	10
256	Predictors of long-term adverse events after Absorb bioresorbable vascular scaffold implantation: a 1,933-patient pooled analysis from international registries. EuroIntervention, 2019, 15, 623-630.	3.2	10
257	Non-Invasive Diagnostic Workup of Patients With Suspected Stable Angina by Combined Computed Tomography Coronary Angiography and Magnetic Resonance Perfusion Imaging. Circulation Journal, 2011, 75, 1678-1684.	1.6	9
258	Randomized comparison of the magnetic navigation system vs. standard wires in the treatment of bifurcations. European Heart Journal, 2011, 32, 1479-1483.	2.2	9
259	The Emerging Application of Remote Ischemic Conditioning in the Clinical Arena. Cardiology in Review, 2012, 20, 279-287.	1.4	9
260	Distance of Lipid Core–Rich Plaques From the Ostium by NIRS in Nonculprit Coronary Arteries. JACC: Cardiovascular Imaging, 2012, 5, 297-299.	5.3	9
261	Plaque Compositional Syntax Score. JACC: Cardiovascular Imaging, 2012, 5, S119-S121.	5.3	9
262	Impact of body mass index on longâ€ŧerm clinical outcomes after secondâ€generation drug eluting stent implantation: Insights from the international global <scp>RESOLUTE</scp> program. Catheterization and Cardiovascular Interventions, 2015, 85, 952-958.	1.7	9
263	VEGF _{165A} microsphere therapy for myocardial infarction suppresses acute cytokine release and increases microvascular density but does not improve cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H396-H406.	3.2	9
264	Association of wall shear stress with long-term vascular healing response following bioresorbable vascular scaffold implantation. International Journal of Cardiology, 2015, 191, 279-283.	1.7	9
265	Differential thrombotic prolapse burden in either bioresorbable vascular scaffolds or metallic stents implanted during acute myocardial infarction. International Journal of Cardiology, 2016, 220, 802-808.	1.7	9
266	Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infrared Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing Coronary Angiography (ATHEROREMO-NIRS Substudy). Current Atherosclerosis Reports, 2018, 20, 52.	4.8	9
267	SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease. PLoS ONE, 2018, 13, e0200076.	2.5	9
268	Optical coherence tomography and coronary revascularization: from indication to procedural optimization. Trends in Cardiovascular Medicine, 2023, 33, 92-106.	4.9	9
269	Cardiac magnetic resonance imaging in stable ischaemic heart disease. Netherlands Heart Journal, 2011, 19, 229-235.	0.8	8
270	Trial participation as a determinant of clinical outcome: Differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology. International Journal of Cardiology, 2013, 169, 305-310.	1.7	8

#	Article	IF	CITATIONS
271	Navvus FFR to reduce CONTRAst, Cost and radiaTion (CONTRACT); insights from a single-centre clinical and economical evaluation with the RXi Rapid-Exchange FFR device. International Journal of Cardiology, 2017, 233, 80-84.	1.7	8
272	Occurrence and predictors of acute stent recoil—A comparison between the xience prime cobalt chromium stent and the promus premier platinum chromium stent. Catheterization and Cardiovascular Interventions, 2018, 91, E21-E28.	1.7	8
273	Clinical outcomes with the STENTYS self-apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction: two-year insights from the APPOSITION III (A Post-Market) Tj ETQo registry. EuroIntervention, 2017, 13, e572-e577.	1 1 0.7843 3.2	314 ggBT /Ove
274	Clinical and angiographic outcomes following first-in-man implantation of a novel thin-strut low-profile fixed-wire stent: the Svelte Coronary Stent Integrated Delivery System first-in-man trial. EuroIntervention, 2013, 9, 125-134.	3.2	8
275	High sensitive TROponin levels In Patients with Chest pain and kidney disease: A multicenter registry — The TROPIC study. Cardiology Journal, 2017, 24, 139-150.	1.2	8
276	Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial. EuroIntervention, 2022, 17, 1467-1476.	3.2	8
277	Semi-automatic border detection method for left ventricular volume estimation in 4D ultrasound data. , 2005, , .		7
278	Efficient Quantification of the Left Ventricular Volume Using 3-Dimensional Echocardiography: The Minimal Number of Equiangular Long-axis Images for Accurate Quantification of the Left Ventricular Volume. Journal of the American Society of Echocardiography, 2007, 20, 373-380.	2.8	7
279	Different Algorithms for Quantitative Analysis of Myocardial Infarction with DE MRI. Academic Radiology, 2011, 18, 1529-1536.	2.5	7
280	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	7
281	Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. Cardiovascular Revascularization Medicine, 2019, 20, 577-582.	0.8	7
282	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 222-230.	3.0	7
283	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7
284	Qualitative and quantitative evaluation of dynamic changes in non-culprit coronary atherosclerotic lesion morphology: a longitudinal OCT study. EuroIntervention, 2018, 13, 2190-2200.	3.2	7
285	Treatment of bioresorbable scaffold failure. EuroIntervention, 2015, 11, V175-V180.	3.2	7
286	The coronary Stent-On-A-Wire (SOAW). EuroIntervention, 2010, 6, 413-417.	3.2	7
287	Three-Dimensional Coronary Anatomy in Contrast-Enhanced Multislice Computed Tomography. Preventive Cardiology, 2002, 5, 79-83.	1.1	6
288	Serial 2- and 3-Dimensional Visualization of Side Branch Jailing After Metallic Stent Implantation. JACC: Cardiovascular Interventions, 2012, 5, 1089-1090.	2.9	6

Robert-Jan M Van Geuns

#	Article	IF	CITATIONS
289	Modified T-Technique With Bioresorbable Scaffolds Ensures Complete CarinaÂCoverage. JACC: Cardiovascular Interventions, 2014, 7, e109-e110.	2.9	6
290	Bioresorbable scaffolds for treatment of coronary bifurcation lesions: Critical appraisal and future perspectives. Catheterization and Cardiovascular Interventions, 2016, 88, 397-406.	1.7	6
291	Impact of Relative Conditional Survival Estimates on Patient Prognosis After Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	6
292	Comparison of acute expansion of bioresorbable vascular scaffolds versus metallic drugâ€eluting stents in different degrees of calcification: An optical coherence tomography study. Catheterization and Cardiovascular Interventions, 2017, 89, 798-810.	1.7	6
293	Association of stentâ€induced changes in coronary geometry with late stent failure: Insights from threeâ€dimensional quantitative coronary angiographic analysis. Catheterization and Cardiovascular Interventions, 2018, 92, 1040-1048.	1.7	6
294	Predicting 2â€year all ause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
295	SYNTAX score in relation to intravascular ultrasound and near-infrared spectroscopy for the assessment of atherosclerotic burden in patients with coronary artery disease. EuroIntervention, 2019, 14, 1408-1415.	3.2	6
296	Long-term Effect of Face-to-Face vs Virtual Reality Cardiopulmonary Resuscitation (CPR) Training on Willingness to Perform CPR, Retention of Knowledge, and Dissemination of CPR Awareness. JAMA Network Open, 2022, 5, e2212964.	5.9	6
297	"Overâ€andâ€under―pericardial covered stent with paclitaxel balloon in a saphenous vein graft. Catheterization and Cardiovascular Interventions, 2010, 75, 964-966.	1.7	5
298	The edge vascular response following implantation of a fully bioresorbable device. International Journal of Cardiology, 2012, 158, 455-457.	1.7	5
299	Evolution of reperfusion post-infarction ventricular remodeling: New MRI insights. International Journal of Cardiology, 2013, 169, 354-358.	1.7	5
300	Indication for percutaneous coronary intervention is not associated with symptoms of anxiety and depression. International Journal of Cardiology, 2013, 168, 4897-4898.	1.7	5
301	Circulating chemokines in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and cardiovascular outcome. Biomarkers, 2014, 19, 611-619.	1.9	5
302	The distressed (Type D) personality mediates the relationship between remembered parenting and psychological distress in cardiac patients. Psychology and Health, 2014, 29, 318-333.	2.2	5
303	Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions. International Journal of Cardiovascular Imaging, 2017, 33, 1863-1871.	1.5	5
304	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). American Journal of Cardiology, 2019, 124, 1833-1840.	1.6	5
305	The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX. Future Cardiology, 2021, 17, 227-237.	1.2	5
306	Identification of anatomic risk factors for acute coronary events by optical coherence tomography in patients with myocardial infarction and residual nonflow limiting lesions: rationale and design of the PECTUS-obs study. BMJ Open, 2021, 11, e048994.	1.9	5

#	Article	IF	CITATIONS
307	Serial quantitative magnetic resonance angiography follow-up of renal artery dimensions following treatment by four different renal denervation systems. EuroIntervention, 2017, 12, e2271-e2277.	3.2	5
308	Bioresorbable vascular scaffolds in left main coronary artery disease. EuroIntervention, 2015, 11, V135-V138.	3.2	5
309	Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial. EuroIntervention, 2012, 8, 352-358.	3.2	5
310	Multislice Computed Tomography for the Evaluation and Follow-Up of Stenting of Aortic Coarctation. Circulation, 2004, 109, e176.	1.6	4
311	Magnetic resonance assessment of left ventricular volumes and mass using a single-breath-hold 3D k-t BLAST cine b-SSFP in comparison with multiple-breath-hold 2D cine b-SSFP. Insights Into Imaging, 2011, 2, 39-45.	3.4	4
312	Association of neointimal morphology by optical coherence tomography with rupture of neoatherosclerotic plaque very late after coronary stent implantation Proceedings of SPIE, 2013, , .	0.8	4
313	Can anxiety and depression, separately or in combination predict subjective health status 10years post-PCI?. International Journal of Cardiology, 2015, 186, 57-59.	1.7	4
314	Very Late Scaffold Thrombosis in Absorb BVS. JACC: Cardiovascular Interventions, 2017, 10, 625-626.	2.9	4
315	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	1.7	4
316	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	1.7	4
317	Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. Clinical Research in Cardiology, 2021, 110, 1543-1553.	3.3	4
318	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clinical Research in Cardiology, 2021, 110, 1680-1691.	3.3	4
319	Non-rigid Groupwise Image Registration for Motion Compensation in Quantitative MRI. Lecture Notes in Computer Science, 2014, , 184-193.	1.3	4
320	Magnetic navigation system assisted stenting of coronary bifurcation lesions. EuroIntervention, 2011, 6, 970-976.	3.2	4
321	Angiographic and histological results following implantation of a novel stent-on-a-wire in the animal model. EuroIntervention, 2012, 8, 390-399.	3.2	4
322	Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008055.	2.2	4
323	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
324	Features of atherosclerosis in patients with angina and no obstructive coronary artery disease. EuroIntervention, 2022, 18, e397-e404.	3.2	4

#	Article	IF	CITATIONS
325	Aberrant Right Subclavian Artery Mimics Aortic Dissection. Circulation, 2000, 101, 459-460.	1.6	3
326	Validation of Renal Artery Dimensions Measured by Magnetic Resonance Angiography in Patients Referred for Renal Sympathetic Denervation. Academic Radiology, 2015, 22, 1106-1114.	2.5	3
327	Use of intracoronary imaging in ST Elevation Myocardial Infarction with coronary artery aneurysm and very late stent thrombosis. International Journal of Cardiology, 2015, 197, 296-299.	1.7	3
328	Everolimus-eluting bioresorbable vascular scaffolds implanted in coronary bifurcation lesions. International Journal of Cardiology, 2016, 221, 656-664.	1.7	3
329	Intermittent pacing therapy favorably modulates infarct remodeling. Basic Research in Cardiology, 2017, 112, 28.	5.9	3
330	The Promus Premier everolimus-eluting platinum chromium stent with durable polymer evaluated in a real world all-comer population in Rotterdam cardiology hospital (the P-SEARCH registry). International Journal of Cardiology, 2017, 240, 103-107.	1.7	3
331	Development and validation of a risk model for longâ€ŧerm mortality after percutaneous coronary intervention: The IDEAâ€BIO Study. Catheterization and Cardiovascular Interventions, 2018, 91, 686-695.	1.7	3
332	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
333	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 547-556.	3.0	3
334	Agreement Between Invasive Wire-Based and Angiography-Based Vessel Fractional Flow Reserve Assessment on Intermediate Coronary Stenoses. Frontiers in Cardiovascular Medicine, 2021, 8, 707454.	2.4	3
335	Essentials of quantitative angiography for bifurcation lesions. EuroIntervention, 2010, 6, J36-J43.	3.2	3
336	Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial. Cardiology Journal, 2016, 23, 626-636.	1.2	3
337	Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome. Arquivos Brasileiros De Cardiologia, 2018, 111, 345-353.	0.8	3
338	Fate of Side-Branch Jailing and a Malapposed Platinum Marker After Resorption of an Everolimus-Eluting Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2015, 8, e53-e54.	2.9	2
339	Ischemic Postconditioning After Routine Thrombus Aspiration During Primary Percutaneous Coronary Intervention: Rationale and Design of the <scp>PO</scp> stconditioning <scp>R</scp> otterdam Trial. Catheterization and Cardiovascular Interventions, 2016, 88, 508-514.	1.7	2
340	Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study. International Journal of Cardiology, 2017, 249, 119-126.	1.7	2
341	Optical Coherence Tomography Assessment forÂPercutaneous Coronary Intervention of the LeftÂMainÂArtery. JACC: Cardiovascular Interventions, 2020, 13, 401-402.	2.9	2
342	Serial intravascular ultrasound observations from the Tryton first-in-man study. EuroIntervention, 2014, 10, 475-483.	3.2	2

#	Article	IF	CITATIONS
343	How should I treat a patient with a stenosed bicuspid aortic valve and an unexpected finding during TAVI?. EuroIntervention, 2014, 9, 1474-1477.	3.2	2
344	How should I treat an unusual referral for heart transplantation?. EuroIntervention, 2010, 5, 861-865.	3.2	2
345	Hangover after Side Branch Stenting: The Discomfort Comes Afterwards. Interventional Cardiology Review, 0, 17, .	1.6	2
346	Noninvasive Coronary Imaging. Circulation: Cardiovascular Imaging, 2008, 1, 89-91.	2.6	1
347	AS-067 Endothelial-Dependent Vasomotion in Coronary Segment Treated by ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System is Related to Plaque Composition at the Time of Bioresorption of the Polymer: Indirect Finding of Vascular Reparative Therapy?. American Journal of Cardiology. 2012. 109. S33-S34.	1.6	1
348	Response to Letter Regarding Article, "Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement― Circulation, 2013, 128, e478-9.	1.6	1
349	Evaluation of 42 cytokines, chemokines and growth factors for prediction of cardiovascular outcome in patients with coronary artery disease. International Journal of Cardiology, 2015, 184, 724-727.	1.7	1
350	Alternative stents in ST-segment elevation myocardial infarction: improving the efficacy of primary percutaneous coronary intervention. Future Cardiology, 2015, 11, 347-357.	1.2	1
351	Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease. International Journal of Cardiology, 2016, 221, 682-687.	1.7	1
352	LBT-6 Two-years Clinical Outcomes Of The ABSORB BVS Compared EES: AÂPropensity Matched Analysis Of The BVS Expand Registry. JACC: Cardiovascular Interventions, 2017, 10, S3.	2.9	1
353	Recurrent Late Bioresorbable Scaffold Thrombosis as a Presenting Symptom of Underlying Cancer. Journal of the American College of Cardiology, 2018, 71, 259-260.	2.8	1
354	Bioresorbable Scaffolds and Bifurcations. Cardiovascular Revascularization Medicine, 2019, 20, 4.	0.8	1
355	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. Atherosclerosis, 2020, 303, 1-7.	0.8	1
356	External validation of the GRACE risk score 2.0 in the contemporary allâ€comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2021, 98, E513-E522.	1.7	1
357	Thin-Strut BRS. JACC: Cardiovascular Interventions, 2021, 14, 1463-1465.	2.9	1
358	Why a EuroIntervention supplement on bifurcation stenting?. EuroIntervention, 2010, 6, J8-J9.	3.2	1
359	Will this trial change my practice? ABSORB II trial (a bioresorbable vascular scaffold versus) Tj ETQq1 1 0.784314	rgBT /Ov	erlock 10 Tf
	Contrast-enhanced cardiac Magnetic Resonance: distinction between cardiac sarcoidosis and		

Contrast-enhanced cardiac Magnetic Resonance: distinction between cardiac sarcoidosis and infarction scar. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 307-314.

0.2 1

#	Article	IF	CITATIONS
361	Acute hemodynamic changes in percutaneous transluminal septal coil embolization for hypertrophic obstructive cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 806-810.	3.3	0
362	Bioresorbable vascular scaffold for ST elevation myocardial infarction. Coronary Artery Disease, 2015, 26, 545-547.	0.7	0
363	11â€Predicting the outcome of reperfusion acutely in patients with STEMI – derivation and validation of the ATI score. Heart, 2016, 102, A6.2-A6.	2.9	Ο
364	TCT-440 Impact of optimal implantation technique on bioresorbable scaffold expansion and one-year clinical outcomes in patients presenting with acute coronary syndromes and calcified lesions. AÂpooled analysis of BVS STEMI First and BVS Expand Studies. Journal of the American College of Cardiology, 2016, 68, B177.	2.8	0
365	Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures― Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	0
366	Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease. Catheterization and Cardiovascular Interventions, 2017, 90, 58-69.	1.7	0
367	155â€Higher igm anti oxidised IdI antibodies point to favourable plaque characteristics as determined by radio frequency intravascular ultrasound (rf-ivus) and near infrared spectroscopy (nirs) in the integrated imaging and biomarker study 3 (ibis-3). Heart, 2017, 103, A112.2-A113.	2.9	0
368	TCT-112 Patient-oriented clinical outcomes and net adverse cardiovascular event in the Global Leaders trial. Journal of the American College of Cardiology, 2018, 72, B49.	2.8	0
369	Can We Keep Our Young Patients Free From Permanent Metallic Implants?. Cardiovascular Revascularization Medicine, 2019, 20, 640-641.	0.8	0
370	Moxy® drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease. EuroIntervention, 2011, 7, 274-277.	3.2	0
371	Magnetic resonance and electron beam tomography coronary angiography. Developments in Cardiovascular Medicine, 1998, , 411-418.	0.1	0
372	Near-infrared spectroscopy predicts events in men and women: Results from the Lipid Rich Plaque study. IJC Heart and Vasculature, 2022, 39, 100985.	1.1	0